The Largest Lung Transplant Program in the Region

Kidney Transplant Clinical Trials	Sponsor	Lead
A Phase III, Randomized, Double-Blind Comparison of Oral Valganciclovir and Placebo for Prevention of CMV Infection after Lung Transplantation	Duke University	Dunitz, Jordan
Aprotinin for Lung Transplantation Patients Attenuating Ischemia/Reperfusion Injury-a Prospective Randomized Trial The main cause of sever morbidity and mortality immediately after lung transplantation is reperfusion induced lung damage and injury leading to long periods of time on the breathing machine or respirator, in the ICU, and hospitals. Because the transplanted lung is highly susceptible to the deleterious effects of ischemia – reperfusion injury, an agent that may combat this process is much sought after in lung transplantation research. For this reason, Aprotinin, a FDA approved serine protease inhibitor that is in wide clinical use in cardiovascular surgery, may be ideally suited to reduce the effects of lung reperfusion injury. It is hypothesized that Aprotinin attenuates the morbid lung ischemia-reperfusion injury and decreases incidence and severity lung damage, edema, bleeding, and blood transfusions in lung transplant recipients.	Bayer Pharma	Hertz, Marshall & Dahlberg, Peter
Lung Transplant Outcomes Database Reports outcomes information on lung and living lobar lung transplant	Internal	Hertz, Marshall
A Randomized, Double Blind, Placebo-Controlled, Phase 3 of the Safety and Efficacy of Subcutaneous Recombinant Interferon gamma-1b (IFN-y1b) in Patients with Idiopathic Pulmonary Fibrosis (RIAF)	InterMune Pharmaceuticals	King Biggs, Melissa
CF Gene Therapy Phase II of aerosolized tgAAVCF for the treatment of CF.	CFTDN	Milla, Carlos
Safety and tolerability study of Aztreonasm for inhalation in CF.	CFTDN and Salus Pharm Inc.	Milla, Carlos